COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia (BVMN6203)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01158807
Recruitment Status : Recruiting
First Posted : July 8, 2010
Last Update Posted : November 1, 2019
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
St. Michael's Hospital, Toronto

Brief Summary:

This study is one of the three projects of an NIH Rare Disease Clinical Research Consortium. A "consortium" is a group of centres sharing information and resources to perform research. The consortium research focuses on brain blood vessel malformations in three different rare diseases.

The focus of this specific study is on Hemorrhagic Telangiectasia (HHT).

HHT is a condition characterized by blood vessel malformations, called telangiectasia and arteriovenous malformations (AVMs), occurring in the brain, nose, lungs, stomach, bowels and liver. Brain AVMs (BAVMs) in HHT are difficult to study because they are rare, affecting approximately 10% of people with HHT. While other types of BAVMs have been studied in depth, studies in the HHT population have been very small. Here, we propose the first large-scale collaboration by joining with 12 HHT Centers of Excellence in North America to perform a large study of risk factors for bleeding from BAVMs, called intracranial hemorrhage (ICH) in HHT patients.

The current standard of clinical practice across North America, is to screen all HHT patients for BAVMs with magnetic resonance imaging (MRI). If BAVMs are detected, patients are referred to a multidisciplinary neurovascular team for consideration for treatment. Treatment decisions are made on a case by case basis, balancing risks of complications from the BAVM with risks of therapy, but are limited by the few studies available in HHT. We hope that the knowledge we obtain about the risk factors for intracranial bleeding in these patients from this larger study will help us to improve the care of HHT patients.

We plan to study risk factors for rupture of BAVMs, including primarily genetics and imaging characteristics of the BAVMs. Knowledge about risk factors will help in the care and management of HHT patients. This will be achieved through the collection of health information to construct a HHT database, blood sampling and banking (through the National Institute of Neurological Disorders and Stroke [NINDS]), and through genetic analysis at the University of California San Francisco.

Condition or disease
Hereditary Hemorrhagic Telangiectasia

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1800 participants
Observational Model: Case-Control
Time Perspective: Other
Official Title: Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia (RDCRN# 6203, Protocol Version Date 07Jan10)
Actual Study Start Date : April 8, 2010
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : September 2024

HHT- Brain Arteriovenous Malformation
  1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and
  2. Presence of Brain Arteriovenous Malformation
1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT

Primary Outcome Measures :
  1. Aim 1: The identification of predictors of brain outcomes in HHT patients [ Time Frame: Through study completion, an average of 5 years ]
    This study will investigate predictors of brain outcomes in HHT patients. The investigators hypothesize that the presence of brain arteriovenous malformation (BAVM) in HHT patients versus HHT patients without BAVM and multiplicity of BAVMs will be associated with worsening functional outcome. Therefore, the comprehensive brain outcomes in HHT for future HHT clinical trials will be characterized.

Secondary Outcome Measures :
  1. Aim 2: A severe bleeding phenotype in HHT will be defined for clinical trial readiness [ Time Frame: Through study completion, an average of 5 years ]
    The investigators hypothesize that weekly nasal bleeding duration in HHT will predict the need for invasive or life-sustaining therapies. HHT participant reported bleeding duration will be measured longitudinally and correlate with the need for invasive or life-sustaining therapies, as well as with ICH risk from BAVMs and with bleeding in other HHT organ phenotypes.

  2. Aim 3: The genetic predictors and circulating biomarkers of severe bleeding and brain outcomes in HHT will be characterized [ Time Frame: Through study completion, an average of 5 years ]
    The investigators hypothesize that there are shared predictors of severe bleeding from the nose and brain in HHT patients, and that identifying these predictors will allow for selection of "at-risk" patients for clinical trials. Specifically, potential genetic, plasma protein biomarker and circulating miRNA biomarker predictors of bleeding will be evaluated. Markers associated with bleeding will then be tested for association with ICH, and with other brain outcomes and HHT severity phenotypes.

Biospecimen Retention:   Samples With DNA
blood and/or saliva

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HHT individuals with a history of brain arteriovenous malformation. HHT individuals without a history of brain arteriovenous malformation.

Inclusion criteria:

  • Definite clinical HHT diagnosis (at least 3 Curacao criteria)or genetic diagnosis of HHT or
  • Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and Presence of Brain Arteriovenous Malformation
  • Able to provide informed consent

Curacao criteria:

  1. spontaneous recurrent nosebleeds;
  2. mucocutaneous telangiectasia at characteristic sites (lips, oral cavity or the nose);
  3. visceral involvement such as pulmonary, hepatic or CNS BAVM; and (d) an affected first degree relative by same criteria.


  • Willingness to participate in the study and ability to give informed consent

Exclusion Criteria:

  • Patients not complying with Inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01158807

Layout table for location information
United States, California
David Geffen School of Medicine at University of California, Los Angeles Recruiting
Los Angeles, California, United States, 90095
Contact: Polly Kay, R.N., CCRP    310-794-0376   
Principal Investigator: Justin McWilliams, MD         
University of California, San Francisco Recruiting
San Francisco, California, United States, 94110
Contact: Dianna Guo    415-476-2677   
Principal Investigator: Michael Lawton, MD         
United States, Connecticut
Yale University Active, not recruiting
New Haven, Connecticut, United States, 06520-8042
United States, Georgia
Georgia Regents University Recruiting
Augusta, Georgia, United States, 30912-3135
Contact: Melissa James, RN    706-721-8391   
Principal Investigator: James R Gossage, MD         
United States, Maryland
Johns Hopkins University School of Medicine Recruiting
Baltimore, Maryland, United States, 21287
Contact: Gina Robinson    410-502-3628   
Principal Investigator: Doris Lin, MD, PhD         
HHT Foundation International, Inc. Recruiting
Monkton, Maryland, United States, 21111
Contact: Marianne S Clancy, RHD, MPA    410-357-9932   
Contact: Nicole Schaefer    410-357-9932   
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Sue Ann Donlinger    507-284-9259   
Principal Investigator: Vivek Iyer, MD         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Sharon Heuerman, RN    314-747-8174   
Principal Investigator: Murali Chakinala, Dr.         
United States, North Carolina
University of North Carolina at Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Karen Smith    919-966-0817   
Principal Investigator: Raj Kasthuri, MD         
United States, Pennsylvania
University of Pennsylvania School of Medicine Withdrawn
Philadelphia, Pennsylvania, United States, 19104
United States, Utah
University of Utah Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Renee Neuharth    801-587-4877   
Principal Investigator: Jamie McDonald, M.S         
Sub-Investigator: Kevin Whitehead, MD         
Canada, Alberta
University of Alberta Active, not recruiting
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
St. Paul's Hospital, University of British Columbia Active, not recruiting
Vancouver, British Columbia, Canada, V6Z 1Y6
Canada, Ontario
St. Michael's Hospital Recruiting
Toronto, Ontario, Canada, M5B 1W8
Contact: Marie E Faughnan, MD MSc FRCPC    416 864 6060 ext 5412   
Contact: Dewi Clark    416-864-6060 ext 2887   
Principal Investigator: Marie Faughnan, MD MSc FRCPC         
Hospital for Sick Children Recruiting
Toronto, Ontario, Canada, M5G 1X8
Contact: Stephanie J Manning    (416) 813 - 4903   
Contact    (416) 813 6167      
Principal Investigator: Felix Ratjen, MD PhD FRCPC         
St. Antonius Hospital Recruiting
Nieuwegein, Netherlands, 3435
Contact: Marleen Peterse-vanSchip    030 - 609 34 59   
Principal Investigator: Hans-Jurgen Mager, MD, PhD         
Sponsors and Collaborators
St. Michael's Hospital, Toronto
National Institute of Neurological Disorders and Stroke (NINDS)
Layout table for investigator information
Principal Investigator: Marie Faughnan, MD MSc FRCPC St. Michael's Hospital, Toronto
Additional Information:
Layout table for additonal information
Responsible Party: St. Michael's Hospital, Toronto Identifier: NCT01158807    
Other Study ID Numbers: RDCRN# 6203
1U54NS065705 ( U.S. NIH Grant/Contract )
First Posted: July 8, 2010    Key Record Dates
Last Update Posted: November 1, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by St. Michael's Hospital, Toronto:
Hereditary Hemorrhagic Telangiectasia
Cerebral arteriovenous malformations
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebral Hemorrhage
Telangiectasia, Hereditary Hemorrhagic
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Hemostatic Disorders
Hemorrhagic Disorders
Hematologic Diseases
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases